Company intelligence / Profile preview

WARPNINE

Subiaco, Western Australia, Australia

Ownership: Private
Development stage: Other

Overview

The iLSTA trial (Phase 1b/2a) combining certepetide (iRGD peptide) with immunotherapy (durvalumab) and chemotherapy (nab-paclitaxel, gemcitabine) for locally advanced, non-resectable pancreatic ductal adenocarcinoma demonstrated a 60% overall response rate (partial response 65%, complete response 5%), 100% disease control rate; 16/20 had decreased CA19-9, with 7 showing >90% reduction. All patients experienced either partial response, complete response, or stable disease, indicating promising early results.

Therapeutic areas: Oncology
Modalities: Peptides (specifically cyclic peptides, e.g., certepetide)ImmunotherapyChemotherapy
Industry: Biotech

Partnerships

Lisata Therapeutics (clinical trial supply and platform partner)

Beyond the preview

Go deeper on WARPNINE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WARPNINE.

Explore the full profile